Evidence map›Paper›PMID 35599603›Full record

ArticleBioengineered2022

SLC8A1 antisense RNA 1 suppresses papillary thyroid cancer malignant progression via the FUS RNA binding protein (FUS)/NUMB like endocytic adaptor protein (Numbl) axis.

Yunchao Xin, Xiaoling Shang, Xiaoran Sun, Guogang Xu, Yachao Liu, Yanbin Liu

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yunchao XinDepartment of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Xiaoling ShangDepartment of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.ORCID 0000-0002-9831-0781
Xiaoran SunDepartment of Gastroenterology, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Guogang XuDepartment of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Yachao LiuDepartment of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Yanbin LiuDepartment of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Hebei North University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Papillary thyroid cancer (PTC) is one of the most prevalent endocrine malignancies and is associated with severe morbidity and high mortality. This study aimed to explore the role of long non-coding RNA (lncRNA) SLC8A1 antisense RNA 1 (SLC8A1-AS1) in the pathogenesis of PTC. In this study, we explored the function of SLC8A1-AS1 in PTC progression. We observed that the expression of SLC8A1-AS1 was downregulated in clinical PTC samples and PTC cell lines compared to that in normal controls. Cell counting kit (CCK)-8 assays demonstrated that the overexpression of SLC8A1-AS1 significantly reduced the proliferation of PTC cells. Consistently, apoptosis of PTC cells was enhanced by SLC8A1-AS1 overexpression. SLC8A1-AS1 overexpression attenuated the invasion and migration of PTC cells. Mechanistically, SLC8A1-AS1 maintained NUMB like endocytic adaptor protein (Numbl) mRNA stability by interacting with FUS RNA Binding Protein (FUS) in PTC cells. Depletion of Numbl reversed the inhibitory effect of SLC8A1-AS1 overexpression on PTC. Thus, we concluded that SLC8A1-AS1 suppresses PTC progression via the FUS/Numbl axis. Our findings provide novel insights into the mechanism underlying SLC8A1-AS1 attenuation of the malignant development of PTC, improving our understanding of the association between lncRNAs and PTC. SLC8A1-AS1 and FUS may be potential targets for PTC treatment.

Indexed as

RNA, AntisenseRNA-Binding Protein FUSRNA, Long NoncodingThyroid NeoplasmsAdaptor Proteins, Signal TransducingCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsThyroid Cancer, PapillaryAdaptor Proteins, Signal TransducingFUS protein, humanIntracellular Signaling Peptides and ProteinsNUMBL protein, humanRNA, AntisenseRNA-Binding Protein FUSRNA, Long NoncodingFUSlncRNA SLC8A1-AS1NumblPapillary thyroid cancerprogression

Identifiers

PMID35599603
PMCPMC9275960
OpenAlexW4281255323

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.